CO2018001985A2 - Polipéptidos mrka, anticuerpos y usos de los mismos - Google Patents

Polipéptidos mrka, anticuerpos y usos de los mismos

Info

Publication number
CO2018001985A2
CO2018001985A2 CONC2018/0001985A CO2018001985A CO2018001985A2 CO 2018001985 A2 CO2018001985 A2 CO 2018001985A2 CO 2018001985 A CO2018001985 A CO 2018001985A CO 2018001985 A2 CO2018001985 A2 CO 2018001985A2
Authority
CO
Colombia
Prior art keywords
mrka
klebsiella
antibodies
fragments
subject
Prior art date
Application number
CONC2018/0001985A
Other languages
English (en)
Inventor
Qun Wang
Saravanan RAJAN
Chew-Shun Chang
Thompson Jenny Heidbrink
Hung-Yu Lin
Charles Kendall Stover
Meghan Pennini
William Dall'acqua
Partha S Chowdhury
Xiaodong Xiao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CO2018001985A2 publication Critical patent/CO2018001985A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación proporciona proteínas de unión a MrkA, p.ej., anticuerpos o fragmentos de unión a antígeno de los mismos que se unen a MrkA e inducen la destrucción opsonofagocítica de Klebsiella (p. ej., Klebsiella pneumoniae). La presente divulgación también proporciona métodos de reducción de Klebsiella (p. ej., Klebsiella pneumoniae) o tratamiento o prevención de infección por Klebsiella (p. ej., Klebsiella pneumoniae) en un sujeto, que comprenden administrar proteínas de unión a MrkA, p. ej., anticuerpos o fragmentos de unión a antígeno de los mismos, polipéptidos MrkA, fragmentos inmunógenos de los mismos, o polinucleótidos que codifican MrkA o fragmentos inmunógenos de los mismos al sujeto.
CONC2018/0001985A 2015-08-24 2018-02-23 Polipéptidos mrka, anticuerpos y usos de los mismos CO2018001985A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
CO2018001985A2 true CO2018001985A2 (es) 2018-11-22

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001985A CO2018001985A2 (es) 2015-08-24 2018-02-23 Polipéptidos mrka, anticuerpos y usos de los mismos

Country Status (16)

Country Link
US (2) US20170073397A1 (es)
EP (1) EP3341004A4 (es)
JP (1) JP2018527924A (es)
KR (1) KR20180042300A (es)
CN (1) CN107921086A (es)
AU (1) AU2016313653A1 (es)
BR (1) BR112018003252A2 (es)
CA (1) CA2995387A1 (es)
CL (1) CL2018000357A1 (es)
CO (1) CO2018001985A2 (es)
HK (1) HK1252350A1 (es)
IL (1) IL257434A (es)
MX (1) MX2018001964A (es)
RU (1) RU2018107056A (es)
TW (1) TW201718626A (es)
WO (1) WO2017035154A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
EP3641828B1 (en) * 2017-06-23 2023-11-22 Affinivax, Inc. Immunogenic compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU2004279441B2 (en) * 2003-10-08 2010-07-01 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
CA2654712C (en) * 2006-06-06 2015-05-05 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2497779A1 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
US8961977B2 (en) * 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US20140011691A1 (en) * 2010-10-26 2014-01-09 Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. Morphology and protein specific reagents as diagnostics for neurodegenerative diseases
ES2859323T3 (es) * 2011-11-07 2021-10-01 Medimmune Ltd Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas

Also Published As

Publication number Publication date
RU2018107056A (ru) 2019-09-26
EP3341004A4 (en) 2019-05-15
CA2995387A1 (en) 2017-03-02
CL2018000357A1 (es) 2018-07-20
MX2018001964A (es) 2018-06-19
AU2016313653A1 (en) 2018-04-12
BR112018003252A2 (pt) 2018-09-25
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
KR20180042300A (ko) 2018-04-25
EP3341004A1 (en) 2018-07-04
JP2018527924A (ja) 2018-09-27
US20190062411A1 (en) 2019-02-28
CN107921086A (zh) 2018-04-17
IL257434A (en) 2018-04-30
WO2017035154A1 (en) 2017-03-02
HK1252350A1 (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CU20170169A7 (es) Anticuerpos de factor xi
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
PE20160528A1 (es) Anticuerpos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
EA201990895A1 (ru) Антитела к о1 и варианты их применения
CO2018001985A2 (es) Polipéptidos mrka, anticuerpos y usos de los mismos
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
EA201990222A1 (ru) Антитела к o2 и пути их применения
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
BR112017013420A2 (pt) anticorpo adam17 humanizado
EA201892068A1 (ru) Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения
ECSP17016757A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno